Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pazopanib plus preoperative radiotherapy for localized non-metastatic soft tissue sarcoma
2015-004134-95Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in soft tissue sarcoma (STS), sponsored by Netherlands Cancer Institute. Primary endpoints: Pathological (near) complete remission rate and Percentage tumor regression in resection specimen. Started Oct 2015; status: active.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2015-004134-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004134-95.